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Crucial Roles of MZF1 and Sp1 in the Transcriptional
Regulation of the Peptidylarginine Deiminase Type I
Gene (PADI1) in Human Keratinocytes
Sijun Dong1,4, Shibo Ying1,4, Toshio Kojima1, Masakazu Shiraiwa1, Akira Kawada2, Marie-Claire Me´chin3,
Ve´ronique Adoue3, Ste´phane Chavanas3, Guy Serre3, Michel Simon3 and Hidenari Takahara1
Peptidylarginine deiminases (PADs) catalyze the conversion of protein-bound arginine residues into citrulline
residues in a calcium-dependent manner. The PAD1 gene (PADI1) is expressed in a few tissues, including the
epidermis, where the protein is detected with a higher level in the more differentiated keratinocytes. Using
quantitative reverse transcription-PCR experiments, we show that PADI1 mRNAs are more abundant in
keratinocytes cultured with 1.2 than 0.15mM calcium. We cloned and characterized the promoter region using
human keratinocytes transfected with variously deleted fragments of the 50-upstream region of PADI1 coupled
to the luciferase gene. We found that as few as 195bp upstream from the transcription initiation site were
sufficient to direct transcription of the reporter gene. Mutations of MZF1- or Sp1-binding sites markedly
reduced PADI1 promoter activity. Chromatin immunoprecipitation assays revealed that MZF1 and Sp1/Sp3 bind
to this region in vivo. Furthermore, MZF1 or Sp1 small interfering RNAs (siRNAs) effectively diminished PADI1
expression in keratinocytes cultured in both low- and high-calcium-containing medium. In addition, the
expression of MZF1 and PAD1 increased in parallel when normal human epidermal keratinocytes underwent
differentiation. These data indicate that MZF1 and Sp1/Sp3 binding to the promoter region drive the PADI1
expression.
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INTRODUCTION
Peptidylarginine deiminase (PAD; EC 3.5.3.15) is a post-
translational modification enzyme that catalyzes the conver-
sion of protein-bound arginine residues into citrulline
residues (protein deimination) in the presence of calcium
ion. This modification significantly alters the charge of
residues from positive to neutral, probably resulting in the
unfolding of target proteins. Although the exact physiological
functions of protein deimination have not been clarified,
keratins, filaggrin, and trichohyalin have been shown to be
deiminated during the terminal stages of epidermal differ-
entiation (Resing et al., 1995; Ishida-Yamamoto et al., 1997).
Moreover, an abnormally decreased level of deiminated
keratin K1 has been reported in the involved areas of the
epidermis of psoriatic patients (Ishida-Yamamoto et al.,
2000). Enhanced deimination of myelin basic protein has
been observed in the brain of multiple sclerosis patients
(Kim et al., 2003) and in primary open-angle glaucoma
(Bhattacharya et al., 2006) and was also found in fibrin/
vimentin in the synovial membrane of rheumatoid arthritis
patients (Nijenhuis et al., 2004; Vincent et al., 2005). These
facts suggested that protein deimination plays an important role
in normal tissue physiological processes and is involved in some
human diseases (Vossenaar et al., 2003; Chavanas et al., 2006).
Since the early reports of PAD activities in the hair follicles
and epidermis of the mammals (Rogers and Taylor, 1977;
Fujisaki and Sugawara, 1981), five isoforms of PAD have
been identified in mammalian tissues and described on the
basis of their cDNA nucleotide sequence and the in vitro
biochemical features of their products (Vossenaar et al.,
2003; Chavanas et al., 2006). Among them, three PAD
isoforms (PAD1, PAD2, and PAD3) are reported to be
expressed in human epidermis (Kanno et al., 2000; Ishigami
et al., 2002; Guerrin et al., 2003); two of them (PAD1 and
PAD3) have also been detected in hair follicles (Terakawa
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et al., 1991; Nachat et al., 2005a). We have reported the
precise cellular localization of the three isoforms in human
and murine epidermis and in human anagen hair follicles by
confocal and immunoelectron microscopy analyses with
highly specific antipeptide antibodies (Me´chin et al., 2005;
Nachat et al., 2005a, b). PAD1 was detected in the entire
epidermis with an increasing intensity gradient from the basal
to the granular layer. PAD2 was detected mainly in both the
spinous and the granular layers with a more intense staining
of the latter, whereas PAD3 expression was shown to be
restricted to the granular layer and lower stratum corneum.
PAD1 and PAD3 were also detected in the inner root sheath
of the hair follicles, whereas PAD3 was the only isoform
expressed in the medulla (Rogers et al., 1997; Kanno et al.,
2000; Nachat et al., 2005b).
These different patterns of location strongly suggest that
the expression of each PAD gene (PADI gene) is tightly
controlled during keratinocyte differentiation. To understand
the regulatory mechanisms involved, we are currently
focusing on the characterization of the proximal promoters
of the human PADI genes and on transcription factors bound
to these control elements in human keratinocytes. Our
previous studies revealed that Sp1/Sp3 function as cis-acting
factors of the human PADI2 gene, whereas the Sp1/Sp3 and
NF-Y transcription factors cooperate to control the transcrip-
tion of PADI3 (Dong et al., 2005, 2006). In this study, we
report on the identification of the minimal promoter of PADI1
and cis-acting elements involved in the regulation of its
expression. Our results indicate that MZF1 and Sp1 are
critical for the expression of PADI1 in keratinocytes.
RESULTS
PADI1 expression in cultured human NHEKs
To investigate the transcriptional regulation of PADI1 in the
epidermis, we initially analyzed its expression by real-time
reverse transcription (RT)-PCR on total RNAs isolated from
primary normal human epidermal keratinocytes (NHEKs)
cultured under low (0.15mM) or high (1.2mM) concentration
of Ca2þ ion and from HeLa cells. As shown in Figure 1,
PADI1 mRNA was detected in NHEKs, with a higher amount
in keratinocytes cultured under high concentration of Ca2þ .
Low expression levels of PADI1 mRNA were detected in
HeLa cells. These results strongly suggest that a high
concentration of Ca2þ stimulates the expression of PADI1
in NHEKs, and that NHEKs are suitable for the study of
transcriptional regulation of the human PADI1 gene.
Identification of the transcription initiation site
Primer extension with the protected RNA segments indicated
that the transcriptional start site was 83 bp upstream of the
translation initiation codon (ATG) (Figure S1). This is
consistent with the fact that the sequence 50-CACACTT-30 at
84 to 78 bp upstream of the translational initiation site
exactly matches the consensus sequence 50-C(A/T)(G/T/C)(T/
C/A)(C/T)(T/G/C)(T/C)-30, where the first ‘‘A’’ indicates the
transcriptional start site frequently used in human genes
(Bucher, 1990). It also corresponds to the 50-end sequence of
PADI1 cDNA (GenBank accession no. AB033768), which
was determined by the 50-RACE method (Guerrin et al.,
2003). Therefore, we determined that the transcriptional start
site ‘‘A’’ of PADI1 (referred to as þ1) was at position 83 bp
upstream of the translation initiation codon.
Promoter activity of the 50-flanking region of PADI1 in cultured
cells
To define the minimal promoter of PADI1, the 50-flanking
region and deletion mutants were cloned into the firefly
luciferase reporter vector pGBasic. Each resulting recombi-
nant plasmid was then transiently transfected into cultured
keratinocytes and the luciferase activities were recorded
after 48 hours (Figure 2a). To define putative differentiation-
responsive regions within the promoters, NHEKs were
incubated in either low- or high-calcium-containing medium.
Higher luciferase activities were detected in NHEKs, as
compared with HeLa cells, with the construct corresponding
to the 50-flanking region of PADI1 (pGB12708/þ84).
Interestingly, a twofold increase in the activity was observed
when NHEKs were shifted from low to high calcium
concentration (Figure 2a). These results are consistent with
the real-time PCR data reported above. They indicate that the
in vitro 2708/þ 84 region is sufficient to drive the
expression of PADI1 and responds to conditions promoting
differentiation of NHEKs. When the deletion mutants were
tested, the luciferase activities of the pGB1195/þ84
construct were comparable to those of the constructs from
pGB1506/þ84 to pGB12708/þ84. Further deletion to
106bp strongly reduced the luciferase activities under all
tested conditions (Figure 2a). These results demonstrated that
the 195/þ 84 region contained the core promoter for
PADI1 gene transcription and was calcium-responsive.
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Figure 1. Expression of PADI1 gene transcripts in NHEKs cultured in high
(1.2mM) or low (0.15mM) Ca2þ ion-containing medium and in the HeLa cell
line. Total RNAs were obtained from semiconfluent cell cultures. The relative
PADI1 mRNA levels were determined in cDNA samples by quantitative real-
time PCR as described in the Materials and Methods section. Data were
normalized to the glyceraldehyde-3-phosphate dehydrogenase gene. Results
are means7SD for four separate experiments. **Po0.01 (Student’s t-test).
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Figure 2. Identification and characterization of the minimal promoter of the PADI1 gene. (a) Identification of the minimal promoter of PADI1. NHEKs
cultured in high- (black bar) and low- (hatched bar) calcium-containing medium and HeLa cells (dotted bar) were transfected with the indicated constructs
and assayed for luciferase activity after 48 hours. The numbers given to the constructs indicate the 50 and 30 ends of the 50-flanking region of PADI1, the
position numbered þ 1 corresponding to the transcription initiation site. Luciferase activity is expressed as fold increase over promoterless vector, pGBasic
(set as 1). Values were normalized for transfection efficiency by cotransfection with the Renilla expression plasmid and are expressed as means7SD for
four separate experiments. **Po0.01 (Student’s t-test). (b) Sequence and putative transcription factor-binding sites of the minimal promoter of PADI1.
Position þ 1 refers to the transcription initiation site. Putative transcription factor-binding sites predicted by searching the BIOBASE P-Match-public v1.0
are underlined. (c) Characterization of the transcription factor-binding sites in the PADI1 promoter by site-directed mutagenesis. Schematic diagram
of serial deletion constructs of the PADI1 promoter and their luciferase activities in NHEKs cultured in high- (black bar) and low- (hatched bar) calcium-
containing medium is shown. The numbers given to the constructs indicate the 50 and 30 ends of the PADI1 promoter region. The targeted putative transcription
factor-binding sites are shown in the constructs with a solid cross. Site-directed mutagenesis was carried out with the construct spanning the 195 to þ84
nucleotides. Values were corrected for transfection efficiency by cotransfection with the Renilla expression plasmid and are expressed as means7SD
for four separate experiments. *Po0.05, **Po0.01 versus the difference between luciferase activity in pG1195/þ 84 and mutant (Student’s t-test).
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Furthermore, pGB1506/þ 84 exhibited the highest activity
among the PADI1 50-flanking region deletions in NHEKs
under low-calcium concentration, and its activity increased
by about 40% compared with pGB1195/þ84 (Figure 2a).
This suggests that some enhancer elements are present
between the 506 and 195 regions.
Searching the transcription factor database of BIOBASE
P-Match-Public, numerous putative transcription factor-binding
sites were identified in the 50-flanking region of PADI1. In
particular, within the 195/þ 84 region near the position of
the transcriptional start site are sequences that closely match
the consensus sequences recognized by MZF1 (four binding
motifs) and Sp1 (one binding motif), suggesting that these
transcription factors are involved in the basic regulation of
PADI1 promoter activity (Figure 2b). Furthermore, luciferase
activities were significantly reduced by mutation of an MZF1-
or the Sp1-binding site compared with the original plasmid.
Mutation of the TATA box completely abolished PADI1
promoter activity (Figure 2c). These results strongly suggest
that the MZF1- and Sp1-binding sites and the TATA box
found between nucleotides 195 and þ84 are cooperative
cis-elements critical for PADI1 promoter activity.
Binding of transcription factors to the PADI1 minimal
promoter
To test whether the predicted transcription factors actually bind
to the PADI1 promoter in vivo, we performed a chromatin
immunoprecipitation (ChIP) assay using specific antibodies,
specific primers for the PADI1 promoter region, and formalde-
hyde-fixed chromatin isolated from cultured cells. As expected,
Sp1 and MZF1 bound to the 50-flanking region of PADI1. Sp3 is
coexpressed with Sp1 in several tissues/cell types and
recognizes the same DNA element (Suske, 1999). Therefore,
we also performed the ChIP assay with Sp3-specific antibody
and showed the binding of Sp3 to the proximal promoter region
of PADI1 (Figure 3a, panel 1). When PCR was performed on the
chromatin samples immunoprecipitated with nonimmune IgG
using the same primers, no PCR signal was observed, showing
the specificity of binding. The input levels of chromatin for each
cell line were shown using nonimmunoprecipitated DNA as
templates for PCR. Further specificity of the ChIP analysis was
shown by the inability to detect binding of Sp1/Sp3 or MZF1 to
exon 2 of PADI1 (Figure 3a, panel 2). To quantify Ca2þ ion
effects on the transcription factor binding, we carried out
quantitative PCR with the immunoprecipitated chromatin
obtained from NHEKs cultured in low- or high-calcium-
containing medium. As shown in Figure 3b, higher levels of
Sp1 and MZF1 recruitment were observed with high Ca2þ
treatments. Interestingly, Sp3 binding was lower when the cells
were cultured with high than with low Ca2þ concentration.
These findings suggest that the association of MZF1 and Sp1/Sp3
on the promoter region of PADI1 may play a prominent role in
the transcription of the gene.
Expression of Sp1 and MZF1 is essential for PADI1 expression in
NHEKs
We carried out siRNA experiments to investigate the roles of
Sp1, Sp3, and MZF1 in vivo in PADI1 gene regulation. As
shown in Figure 4a, the siRNAs transferred hindered the
synthesis of each transcription factor by NHEKs in a specific
manner. When Sp1 expression was reduced by specific
siRNA transfection, the level of PADI1 transcription in the
cells cultured in both low- and high-calcium-containing
medium was diminished significantly by more than 40%
(Figure 4b). When MZF1 expression was reduced by a
specific siRNA, the level of PADI1 expression in NHEKs
cultured under both conditions was decreased by more than
30% (Figure 4b). However, when the Sp3 expression level
was effectively silenced by Sp3-specific siRNA, the levels of
PADI1 expression were not significantly affected (Figure 4b).
Control siRNA did not significantly affect PADI1 expression.
These data demonstrate that Sp1 and MZF1 are necessary for
the transcription of PADI1 in NHEKs.
High calcium induces NHEK differentiation and expression of
PAD1 and MZF1
To investigate the effects of high calcium on the keratinocyte
differentiation and expression of PAD1 and MZF1, we carried
out Western blot analyses of the total proteins extracted from
1.2mM Ca2þ -treated NHEKs and 0.15mM Ca2þ -treated
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Figure 3. Sp1, Sp3, and MZF1 binding to the PADI1 promoter in vivo. ChIP
assays using anti-Sp1, anti-Sp3, or anti-MZF1 antibodies and without any
antibodies were performed using chromatin from NHEKs cultured in low- (L)
or high- (H) calcium-containing medium as described in the Materials and
Methods section. (a) Sp1, Sp3, or MZF1 binding to the PADI1 promoter was
detected by gel staining after PCR amplification using primers corresponding
to the promoter region (panel 1) and exon 2 (panel 2, negative control) of
PADI1. Sizes are given in bp. (b) For quantitative analyses of Sp1, Sp3, and
MZF1 binding to the PADI1 promoter, the samples from NHEKs cultured in
low- (hatched bar) and high- (black bar) calcium-containing medium were
analyzed using real-time PCR. The relative DNA levels were calculated as
described in the Materials and Methods section. Results are means7SD for
four separate experiments. *Po0.05, **Po0.01 (Student’s t-test).
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NHEKs as control. As shown in Figure 5, the expression of K1
and K10, two markers of keratinocyte differentiation, was
detected from 48hours of high-calcium induction and
increased to a maximum level at 96 hours. In a similar way,
the level of PAD1 gradually increased after stimulation with
high calcium. The expression level of MZF1 was significantly
increased after 48 hours of high-calcium induction, up to a
maximum level after 96 hours, supporting its role in
upregulating the PADI1 transcription. Neither K1/K10 ex-
pression nor changes in PAD1 or MZF1 detection level were
clearly observed using control cells cultured in low-calcium-
containing medium.
DISCUSSION
In this study, the regulatory mechanisms of PADI1 gene
expression were studied by cloning and functional character-
ization of the promoter region in human keratinocytes. One
putative Sp1- and four putative MZF1-binding sites showed
significant effects on PADI1 promoter activity. Further
comparison of regions of about 200 nt upstream of the
transcription initiation sites of PADI1 and PADi1, the mouse
orthologous gene, revealed extensive identities including
these putative binding sites (Figure S2). On the basis of
these facts, we suspected these conservative cis-elements
could function as key regulators for the basal expression
of the PADI1 gene in mammalian tissues. Moreover, similar
to the increased detection of PAD1 in the epidermis
throughout the course of differentiation (Nachat et al.,
2005b), we showed that the expression of PADI1 was
enhanced at both the transcriptional and the protein level
in NHEKs cultured in 1.2mM calcium as compared to
0.15mM. This suggests that NHEKs might be an excellent
system in vitro for studying the molecular basis of PADI1
gene regulation (Figures 1 and 5).
We demonstrated that Sp1 bound to the PADI1 promoter
in vivo (Figures 3b and 4). Sp1 is the prototypical member of
the Sp/Kru¨ppel-like family of zinc-finger proteins that
function as transcription factors in mammalian cells (Kac-
zynski et al., 2003). Since its identification in 1983 (Dynan
and Tjian, 1983), Sp1 has been shown to regulate many genes
and may take part in virtually all facets of cellular function,
including cell proliferation, apoptosis, and differentiation
(Suske, 1999). It was originally identified as a ubiquitous
transcription activator that was implicated in the constitutive
expression of a considerable number of genes, including
PADI2 and PADI3 (Dong et al., 2005, 2006). Sp1 regulates
the transcription of a number of TATA-containing promoters,
often coordinating with other cellular transcription factors
depending on which promoter they bind to and the
coregulators with which they interact in a tissue-, cell-, and
promoter-specific manner (Suske, 1999; Kaczynski et al.,
2003; Lomberk and Urrutia, 2005; Douet et al., 2007).
Moreover, recent studies have revealed the existence of an Sp
family, with Sp1 and Sp3 being characterized extensively and
known to be coexpressed in several tissues/cell types and to
interact with an identical consensus sequence (Suske, 1999;
Safe and Abdelrahim, 2005). Furthermore, Sp3 expression
can either activate or repress promoter activity, depending on
the promoter and type of cell (Pagliuca et al., 2000;
Ammanamanchi and Brattain, 2001; Ammanamanchi et al.,
2003). In human epidermis, Sp1 is an important regulator of
genes involved in epidermal differentiation, including those
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PAD1 and MZF1. NHEKs were cultured in 0.15mM calcium-containing
medium as control (a) or exposed to 1.2mM calcium (b) for the indicated length
of time. Proteins were extracted with SDS buffer and analyzed by Western
blotting using anti-PAD1, anti-MZF1, or anti-K1/K10 antibodies. K1 and K10
were used as differentiation marker. Actin was used as a loading control.
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Figure 4. Binding of Sp1 and MZF1 to the PADI1 promoter is essential for
PADI1 expression in NHEK. NHEKs were transfected with the indicated
siRNA at 100 nM and cultured for 36 hours. Nuclear proteins and total RNA
were extracted for Western blotting with the indicated antibodies and
quantitative real-time PCR analysis, respectively. (a) Inhibition of expression
of Sp1, Sp3, and MZF1 with their respective specific siRNAs was confirmed
by Western blotting, as compared with control siRNA treatments and with
treatments without any siRNA (none). The levels of the nuclear isoform of
actin were used as loading controls. (b) Effects of inhibition of Sp1, Sp3, and
MZF1 on PADI1 expression. PADI1 expression level in NHEKs cultured in
low- (hatched bar) and high- (black bar) calcium-containing medium was
normalized to the level of expression of glyceraldehyde-3-phosphate
dehydrogenase and expressed relative to the nontreated NHEKs cultured in
low-calcium-containing medium. Results are means7SD for four
experiments. **Po0.01 (Student’s t-test).
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of keratin 5, involucrin, loricrin, transglutaminase (Nakamura
et al., 2007), and PAD2 and -3 (Dong et al., 2005, 2006). In
our study, ChIP assays indicated that the amounts of Sp1 and
Sp3 recruitment to the PADI1 promoter and the Sp1/Sp3 ratio
changed according to the concentration of calcium in the
NHEK culture medium, in a way consistent with the levels of
PADI1 mRNA detected by real-time RT-PCR. This suggests
that the ratio of Sp1 and Sp3 binding may be responsible for
the induced expression of PAD1 in the upper keratinocyte
layers of epidermis. The calcium gradient observed in the
tissue is known to be involved in keratinocyte differentiation
(Hennings et al., 1980). However, reduction of Sp3 expres-
sion using specific siRNA did not significantly influence the
level of basal and Ca2þ -enhanced PADI1 expression (Figure
4b). Therefore, it is possible that the absence of Sp3 could be
compensated for by Sp1, but not the reverse, or that the
remaining amount of Sp3 after siRNA treatment is still
sufficient to regulate the transcription of PADI1, or that other
transcription factors may be involved.
Our results (Figures 3–5) also strongly indicated the
binding of MZF1 to the core promoter region of PADI1 and
the involvement of this transcriptional factor of the Kru¨ppel
family in accounting for the differentiation-specific expres-
sion of PADI1. Interestingly, MZF1-binding sites have not
been identified in the promoter regions of PADI2 and -3
(Dong et al., 2005, 2006). MZF1 was found to play a key role
in cell lines representing early stages of myeloid differentia-
tion and derivation of ES cell lines (Perrotti et al., 1995)
involved in growth, differentiation, and apoptosis of myeloid
progenitors and regulating transcription during differentiation
along the myeloid lineage (Bavisotto et al., 1991; Hromas
et al., 1991; Perrotti et al., 1995). Moreover, MZF1 is reported
to be a bifunctional transcription regulator, containing 13
C2H2 zinc-finger domains divided into two groups that can
bind DNA independently, depending on the cellular envir-
onment (Hromas et al., 1996; Le Mee et al., 2005). However,
so far, the function of MZF-1 in transcription regulation has
been unexplored in human keratinocytes. Thus, cis-acting
motifs of MZF1 in transcriptional regulation in keratinocytes
will be of future interest. We found that two of the four MZF1-
binding sites (nt positions 73 and 163) were clearly the
most important in the response to high Ca2þ treatment,
especially the most proximal to the TATA box. This site was
also the most confident, with a P-value of 1.0 in the in silico
motif search. These observations suggested that the two sites
might be critical as two main binding sites of MZF1. In
addition, the other two MZF1 sites on either side of the Sp1-
binding site also retained certain calcium sensitivity and may
ensure adequate expression of PADI1. It could be that MZF1
binding to these two sites may be weaker due to the binding
of and blocking by Sp1. However, we also cannot exclude
the possibility that a cooperation between MZF1 and Sp1
may exist in specific cell or tissue types or in response to a
specific condition. MZF1 probably acts as an activator of the
basic transcriptional activity during cell proliferation, which
in response to extracellular Ca2þ initiate signaling cascades
that lead to the promotion of PADI1 expression during early
cell differentiation (Figure 5).
As the extracellular Ca2þ concentration in the epidermis
increases from the basal layer to the stratum granulosum
(Bikle et al., 2004), it is likely that the level of Ca2þ results in
PADI1 gene regulation in the different keratinocyte layers
through the distribution/activity of transcription regulators
such as Sp1/Sp3 and MZF1, which may direct keratinocyte-
specific and differentiation-specific expression.
The five PAD genes share significant similarity in their
organization and have evolved from a common ancestral
gene (Chavanas et al., 2004). However, the nucleotide
sequences of their 50-flanking regions are not conserved,
and mechanisms for their regulation seem to be diverse.
Indeed, PADI2 is widely expressed in a variety of tissues
(Ishigami et al., 2002), whereas other PADI genes are tissue-
specifically expressed (Chavanas et al., 2006). PADI2
contains a TATA-less but GC-rich 50-flanking region (Dong
et al., 2005), whereas PADI1 (this study), PADI3 (Dong et al.,
2006), and PADI4 (Dong et al., 2007) are likely to be
regulated by TATA-box-containing promoters. Interestingly,
in our previous studies, we discovered that Sp1/Sp3 was
involved in the regulation of PADI2, -3, and -4 gene
expression (Dong et al., 2005, 2006, 2007), whereas NF-Y
was involved in one of either PADI3 or -4 (Dong et al., 2006,
2007). It might be one of the key issues that the level of Ca2þ
changing within the different keratinocyte layers in human
epidermis results in PADI gene regulation through the
distribution/activity of transcription regulators such as Sp1,
Sp3, MZF1, and NF-Y.
In conclusion, the identification of the human PADI1
minimal promoter and of transcription factors bound onto it,
as presented in this study, will help to identify the regulatory
mechanisms involved in tissue- and differentiation stage-
specific expression of the human PAD1 genes and, more
generally, in the control of the complex differentiation
program of keratinocytes necessary for human skin home-
ostasis or pathology. As the importance of PADs in skin and
other tissue diseases such as multiple sclerosis and rheuma-
toid arthritis is becoming clearer (Kim et al., 2003; Sebbag
et al., 2004; Chavanas et al., 2006), it is crucial to investigate
the mechanisms of their accurate regulation, including
transcriptional and translational controls, which may pave
the way to regulating abnormal deimination, taking PADs as
possible therapeutic targets in the future.
MATERIALS AND METHODS
All experiments were conducted in accordance with the Declaration
of Helsinki Principles and were approved by the Ibaraki University
Ethical Committee of Human Genome and Gene Research.
Cell cultures
NHEKs were obtained from Clonetics (San Diego, CA) and cultured
in KGM2 (Clonetics, San Diego, CA) with either 0.15mM (proliferat-
ing conditions) or 1.2mM Ca2þ (differentiating conditions) as
described previously (Hennings et al., 1980). Unless specifically
indicated, NHEKs were exposed to 1.2mM Ca2þ for 96 hours to
induce the differentiation. HeLa cells were obtained from Health
Sciences Research Resources Bank (Osaka, Japan) and maintained in
DMEM (Gibco-BRL, Rockville, MD) with 10% (v/v) fetal bovine
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serum (HyClone Laboratories, Logan, UT). All the cells were
incubated at 371C with 5% CO2. After reaching 70–80% confluence,
the cells were collected for subculture or transfection.
Real-time RT-PCR analysis
The relative expression values of PADI1 were analyzed by real-time
RT-PCR, as described previously (Dong et al., 2005). The following
primer pair was used to amplify a 104bp fragment of PADI1 exon 2: a
forward primer, 50-GTCTACAACCGCACACGT-30 (positions 240–257
of the human PAD1 cDNA: GenBank accession no. AB033768), and a
reverse primer, 50-AATTCCTTACTGGCTGTGC-30 (positions 343–325).
The amount of cDNA was normalized in PCR controls with primers
specific to glyceraldehyde-3-phosphate dehydrogenase: forward pri-
mer, 50-CATGTTCCAATATGATTCCAC-30 (positions 187–207 of the
human glyceraldehyde-3-phosphate dehydrogenase cDNA: accession
no. M33197), and reverse primer, 50-CCTGGAAGATGGTGATG-30
(positions 271–287). Real-time quantitation was performed using the
SuperScriptTM III PlatinumR Two-Step qRT-PCR with SYBRR Green Kit
(Invitrogen, Carlsbad, CA) and iCycler IQTM detection system (Bio-Rad,
Hercules, CA). After denaturation at 951C for 3minutes, amplification
was carried out for 50 cycles using a two-step protocol: at 951C for
30 seconds and at 581C for 30 seconds.
Cloning of the 50-flanking region of PADI1
Based on the nucleotide sequences from the human genomic contig
(GenBank accession no. NT 030584.7), the 50-flanking region
of PADI1 was amplified by two-step PCR. In brief, the first PCR
was performed with human genomic DNA (BD Biosciences, Palo
Alto, CA) as a template and the specific human PADI1 primer pair
50-AGTCTTGCTCTGTTGC-30 (forward: 2708 to 2693) and
50-TGTGAATGTCCACATG-30 (reverse: þ 158 to þ 174). The PCR
conditions were 951C for 2minutes, 30 cycles (951C for 30 seconds,
481C for 30 seconds, and 721C for 4minutes), and 721C for 8minutes
with Ex Taq DNA polymerase (Takara, Shiga, Japan) according to the
manufacturer’s instructions. Subsequently, nested PCR was carried
out with the resulting DNA fragments and forward primer G1-2708/
2689 and reverse primer G1-RV (Table S1); the conditions were
951C for 1minute, 30 cycles (951C for 30 seconds, 551C for
30 seconds, and 721C for 4minutes), and 721C for 8minutes. The
final products of the nested PCR were subcloned into the pGEMR-T
vector (Promega, Madison, WI). The obtained plasmid, pTAhPAD1,
covered a 2791-bp nucleotide sequence of the 50 region of PADI1.
Sequencing of each clone was carried out on an automated DNA
sequencer (373 DNA Sequencer, Applied Biosystems, Foster City, CA).
RNase protection analysis
To determine the 50 end of PADI1 mRNA, RNase protection assays
were performed as described before (Dong et al., 2005). These
procedures are provided in detail in the Supplementary Materials
and Methods.
Searching the conserved noncoding segments and
transcriptional motifs
The sequence of the 50-flanking regions of mouse Padi1 was
obtained through searching the chromosome 4 contig AL645625.
The program DNA Block Aligner (http://www.ebi.ac.uk/
Wise2/dbaform.html) was used to analyze both the sequences of
human and mouse (Jareborg et al., 1999). The putative transcription
factor-binding sites were characterized by searching the BIOBASE
P-Match-Public v1.0 (http://www.gene-regulation.com/index.html;
group of matrices was vertebrate; cutoffs for core and matrix
similarity were 1.0 and 0.90, respectively).
Construction of promoter reporter plasmids
A KpnI–BglII fragment (covering 2708 to þ 84 bp from the
transcriptional start site) of pTAhPAD1 was inserted into the
KpnI–BglII sites of pGBasic vector 2 containing the firefly luciferase
gene (Nippon Gene, Toyama, Japan). Sequential 50-deletion
constructs of the 50-flanking region of PADI1 were generated by
PCR using pG1-2708/þ 84 as a template and primers listed in Table S1.
The thermocycler settings were 951C for 2minutes, 30 cycles (951C for
30 seconds, 30 seconds at the predicted melting temperature of each
forward primer, 721C for 3minutes), and 721C for 10minutes. The
amplification products were ligated into the KpnI–BglII sites of pGBasic.
To construct promoter reporter plasmids with site mutations, PCR was
performed using pG1-195/þ 84 as the template and the Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA). The six pairs of oligonucleo-
tides used in thermal cycling are listed in Table S1. All mutation
constructs were confirmed by DNA sequencing.
Transfection and measurement of promoter activity
Transfection and measurement of promoter activities were carried
out following procedures described previously (Dong et al., 2005).
Four transfections were carried out independently for each construct,
and the results were expressed as means7SD.
ChIP assays
ChIP assays were performed as described in the protocol of the
Chromatin Immunoprecipitation Assay Kit (Upstate, Lake Placid,
NY). Immunoprecipitation was performed overnight with agitation at
41C with 5mg of normal IgG, anti-MZF1, anti-Sp1, or anti-Sp3
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). Immuno-
precipitated chromatin was collected and analyzed by conventional
PCR and quantitative PCR. The following primers were used for ChIP
PCR analysis to amplify the promoter region from nucleotide 174
to 45: 50-TCCCCTTCCCCATCTCCCA-30 (forward; nucleotides
174 to 156) and 50-CTGCGACCTGATTAGCCTGG-30 (reverse;
nucleotides 64 to 45). The amplification program consisted of
denaturation at 951C for 3minutes, followed by 40 cycles of 951C for
15 seconds, 601C for 10 seconds, and 721C for 10 seconds. The
control PCR for ChIP analysis was performed using the primers and
conditions described above under ‘‘Real-time RT-PCR analysis.’’
siRNA-based inhibition
NHEKs were transfected using the siRNA transfection reagent (Santa
Cruz Biotechnology) with 100 nM siSp1, siSp3, siMZF1, or siControl
(Santa Cruz Biotechnology) according to the manufacturer’s instruc-
tions. After the cells were cultured in antibiotic-free medium for
48 hours, total RNA was extracted and analyzed by real-time RT-
PCR as described above. To confirm the specific inhibitory activity of
each siRNA, we carried out Western blotting analyses with the
antibodies against each transcription factor as described below.
Western blotting
Total proteins were extracted with SDS buffer (0.125M Tris–HCl, pH
6.8, 10% 2-mercaptoethanol, 4% SDS, and 10% sucrose) and
www.jidonline.org 555
S Dong et al.
Regulation of PADI1 in Human Keratinocytes
sonicated on ice for 30 seconds. The nuclear extracts were prepared
from untreated or siRNA-transfected cells as described previously
(Dong et al., 2005). Primary anti-PAD1 (Nachat et al., 2005b), anti-
K1/K10 (EE21-06, Barbaud et al., 1998), anti-MZF1, anti-Sp1, anti-
Sp3, or anti-actin antibodies (Santa Cruz Biotechnology) were added
in skimmed milk solution at a sufficient dilution (1:200–1:10,000). The
secondary anti-rabbit, anti-mouse, or anti-goat (Santa Cruz Biotech-
nology) antibodies were used at a dilution of 1:3,000, 1:5,000, or
1:12,000, respectively. The proteins were detected using the ECL
(enhanced chemiluminescence) Plus Western blotting detection
system (Amersham Pharmacia Biotech; Arlington Heights, IL).
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